Intellia Therapeutics, Inc. Operating Income Loss

• Intellia Therapeutics, Inc. showed an increase of +17.5% in Operating Income Loss from 2024 to 2025.
• This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Operating Income Loss has declined by 3,188.8%.
• Historical annual values: Fiscal year 2025: -$440.99 million | Fiscal year 2024: -$534.26 million | Fiscal year 2023: -$515.29 million | Fiscal year 2022: -$458.16 million | Fiscal year 2021: -$267.85 million | Fiscal year 2020: -$136.58 million | Fiscal year 2019: -$106.37 million | Fiscal year 2018: -$90.87 million | Fiscal year 2017: -$69.56 million | Fiscal year 2016: -$32.16 million | Fiscal year 2015: -$13.41 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026